Phase 3 Marketing and Communications Revenue and Competitors

Vinings, GA USA

Location

N/A

Total Funding

Marketing

Industry

Estimated Revenue & Valuation

  • Phase 3 Marketing and Communications's estimated annual revenue is currently $34M per year.(i)
  • Phase 3 Marketing and Communications's estimated revenue per employee is $250,000

Employee Data

  • Phase 3 Marketing and Communications has 136 Employees.(i)
  • Phase 3 Marketing and Communications grew their employee count by -6% last year.

Phase 3 Marketing and Communications's People

NameTitleEmail/Phone
1
Co-Founder and CIOReveal Email/Phone
2
Co-Founder & PresidentReveal Email/Phone
3
Sr VP / General ManagerReveal Email/Phone
4
SVP, Digital Programming & DevelopmentReveal Email/Phone
5
VP, OperationsReveal Email/Phone
6
SVP, SalesReveal Email/Phone
7
VP, SalesReveal Email/Phone
8
VP SalesReveal Email/Phone
9
SVP, PR and Client EngagementReveal Email/Phone
10
SVP, Marketing and Business DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.8M445%N/AN/A
#2
$15.5M6917%N/AN/A
#3
$14.9M66-11%N/AN/A
#4
$0.5M40%N/AN/A
#5
$16.4M73-15%N/AN/A
#6
$153.4M491N/AN/AN/A
#7
$16.2M72-1%N/AN/A
#8
$2M130%N/AN/A
#9
$4.9M280%N/AN/A
#10
$8.4M42-5%N/AN/A
Add Company

What Is Phase 3 Marketing and Communications?

Nestled within Atlanta’s Fairlie-Poplar District between Fairlie and Forsyth Street, our downtown Atlanta offices boast historic charm and a recently renovated interior. The site is adjacent to the Georgia State Campus and walking distance to CNN Center and Centennial Olympic Park.

keywords:N/A

N/A

Total Funding

136

Number of Employees

$34M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Phase 3 Marketing and Communications News

2022-04-20 - BeiGene Presents Updated Results from Phase 3 ...

BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 ... and marketing of tislelizumab in the U.S., Europe and Japan.

2022-04-20 - Plinabulin noninferior to pegfilgrastim for chemotherapy ...

We then proceeded to this phase 3 study of single-agent plinabulin ... the FDA was not convinced to approve marketing of plinabulin in the...

2022-04-20 - Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal ...

Updated Phase 3 SIERRA data to be presented in an oral presentation ... acceptable as the basis for a Marketing Authorization Application.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$39.4M1360%N/A
#2
N/A13972%N/A
#3
$21M141N/AN/A
#4
$750M146-7%N/A
#5
$27.3M1476%N/A